Biotech Stocks Rally on Drug Innovation and M&A

Biotech stocks are rallying on drug innovation and M&A. The iShares Biotechnology ETF (IBB) is up 24% through October 23, building on a 28% gain in 2025. Two dozen holdings have more than doubled year-to-date. Moderna leads with a 587% surge. Analysts attribute gains to clinical trial results, M&A and technologies like mRNA, genomics and AI. Recent approvals and pipeline drugs fuel optimism. The sector recovered from a fallow period with positive Phase 3 results and new modalities. Investors see potential in personalized treatments and obesity drugs. This reflects a new biotech cycle.

Could this boost biotech investments or affect drug prices? Rally driven by innovation and M&A; no specific price impact on consumer drugs announced.